Evidence map›Paper›PMID 42786305›Full record

ArticleNature medicine2026

Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial.

Kohei Shitara, Zev Wainberg, Josep Tabernero, Eric Van Cutsem, Clélia Coutzac, Christelle De La Fouchardière, Jeeyun Lee, Sun Young Rha, Yoon-Koo Kang, Philip Fanning and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kohei ShitaraNational Cancer Center Hospital East, Kashiwa-shi, Japan.ORCID http://orcid.org/0000-0001-5196-3630
Zev WainbergRonald Reagan UCLA Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-7142-1246
Josep TaberneroVall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IIS IR-HUVH, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2495-8139
Eric Van CutsemUniversity Hospitals Gasthuisberg & KU Leuven, Leuven, Belgium.
Clélia CoutzacCentre Léon Bérard, Lyon, France.ORCID http://orcid.org/0000-0002-8347-6957
Christelle De La FouchardièreInstitut Paoli-Calmettes, Marseille, France.
Jeeyun LeeSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID http://orcid.org/0000-0002-4911-6165
Sun Young RhaYonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.ORCID http://orcid.org/0000-0002-2512-4531
Yoon-Koo KangAsan Medical Center, University of Ulsan, Seoul, Korea.
Philip FanningALX Oncology, South San Francisco, CA, USA.
Alison ForgieALX Oncology, South San Francisco, CA, USA.
Cherry MaoALX Oncology, South San Francisco, CA, USA.
Daniel BrickmanALX Oncology, South San Francisco, CA, USA.ORCID http://orcid.org/0009-0004-9993-0116
Jaume PonsALX Oncology, South San Francisco, CA, USA.
Athanasios C TsiatisALX Oncology, South San Francisco, CA, USA.
Sophia RandolphALX Oncology, South San Francisco, CA, USA.
Keun-Wook LeeSeoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. imdoctor@snu.ac.kr.ORCID http://orcid.org/0000-0002-8491-703X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evorpacept blocks the CD47-signal regulatory protein α interaction, enhancing antibody-dependent cellular phagocytosis. In the phase 2 portion of ASPEN-06 (a multicenter, open-label, randomized phase 2/3 study), 127 patients with pretreated, human epidermal growth factor receptor 2 (HER2)-overexpressing, advanced gastric/gastroesophageal junction cancer were randomized to evorpacept plus trastuzumab, ramucirumab and paclitaxel (evo + TRP; n = 63; fresh HER2

Identifiers

PMID42786305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.